Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
NCT05819853
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
- Obese
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 12 to 35 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- August 31, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Anschutz/Children's Hospital Colorado Aurora · Aurora, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.